Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Choosing oral solid-dosage production processes: Could a classification system help?

April 02, 2015

A drug-product manufacturing classification system (MCS) for oral solid-dosage forms is proposed by an Academy of Pharmaceutical Sciences working group.

An Orthogonal Approach to Biosimilarity

April 02, 2015

In this article, industry experts discuss critical analyses for demonstrating biosimilarity.

Welcome to the Biosimilar Era

April 02, 2015

FDA approves a biosimilar and loses a commissioner in March.

Multivariate Data Analysis Finds Use In Biopharmaceutical Process Development And Scale-Up

April 02, 2015

Multivariate data analysis (MVDA) is being used to effectively handle complex datasets generated by process analytical technology (PAT) in biopharmaceutical process development and manufacturing.

Merck Joins CAR T-cell Market with $941 Million Intrexon Alliance

March 31, 2015

Merck Serono announces that it will work with Intrexon to develop a cancer therapy using chimeric antigen receptor T-cells.

Rentschler Commissions 2000-L Single-Use Bioreactor

March 30, 2015

Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.

Industry Responds to FDA Labeling Rule

March 30, 2015

Drug makers back alternative to FDA labeling update rule.

FDA Denies Amgen's Certification Petition in Biosimilar Patent Dance

March 30, 2015

Biosimilar applicants will not be required to hand over their biosimilar applications and manufacturing dossiers to innovator companies, determines FDA.

FDA Expands Usage of Regeneron’s Eylea

March 26, 2015

FDA has approved another indication for Eylea, a treatment for diabetic retinopathy in patients with diabetic macular edema.

Emergent Dives Further into the Anthrax Treatment and Vaccine Market

March 25, 2015

Emergent BioSolutions announced FDA approval of Anthrasil, an inhalable treatment that targets Anthrax toxins, as well as a contract with BARDA to develop NuThrax, an anthrax vaccine candidate.